Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA:600867)
China · Delayed Price · Currency is CNY 8.57
-0.02 (-0.23%)
Aug 14, 2026, 3:00 PM CST
SHA:600867 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 16,764 | 15,878 | 15,712 | 21,483 | 18,210 | 22,161 | |
Market Cap Growth | 1.00% | 1.06% | -26.86% | 17.97% | -17.83% | -17.92% |
Enterprise Value | 15,641 | 15,011 | 15,837 | 20,921 | 16,966 | 21,321 |
Last Close Price | 8.57 | 7.87 | 7.52 | 9.85 | 8.16 | 9.20 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.13 | 13.03 | - | 18.40 | 11.51 | 16.94 |
Forward PE | 25.97 | 31.42 | 42.42 | 20.43 | 16.39 | 23.83 |
PS Ratio | 5.51 | 5.39 | 7.82 | 6.99 | 6.55 | 6.78 |
PB Ratio | 2.32 | 2.23 | 2.45 | 2.98 | 2.78 | 3.56 |
P/TBV Ratio | 2.51 | 2.42 | 2.73 | 3.28 | 3.01 | 3.80 |
P/FCF Ratio | 51.96 | 92.57 | - | 41.84 | 49.19 | 38.23 |
P/OCF Ratio | 19.65 | 23.04 | 33.98 | 24.94 | 21.10 | 18.77 |
PEG Ratio | - | 2.07 | 2.07 | 1.31 | 1.31 | 1.31 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.14 | 5.09 | 7.88 | 6.80 | 6.11 | 6.52 |
EV/EBITDA Ratio | 16.70 | 17.77 | 52.39 | 14.37 | 16.42 | 15.35 |
EV/EBIT Ratio | 24.11 | 25.78 | 138.31 | 16.47 | 19.23 | 17.12 |
EV/FCF Ratio | 48.48 | 87.51 | - | 40.75 | 45.83 | 36.78 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.09 | 0.07 | 0.11 | 0.02 | 0 | 0 |
Debt / EBITDA Ratio | 0.73 | 0.62 | 2.29 | 0.10 | 0.00 | 0.00 |
Debt / FCF Ratio | 2.12 | 3.07 | - | 0.29 | 0.01 | 0.01 |
Net Debt / Equity Ratio | -0.15 | -0.14 | 0.01 | -0.14 | -0.13 | -0.14 |
Net Debt / EBITDA Ratio | -1.21 | -1.15 | 0.16 | -0.69 | -0.82 | -0.65 |
Net Debt / FCF Ratio | -3.48 | -5.66 | -0.46 | -1.97 | -2.28 | -1.55 |
Asset Turnover | 0.39 | 0.39 | 0.27 | 0.42 | 0.42 | 0.53 |
Inventory Turnover | 1.30 | 1.23 | 0.76 | 0.91 | 1.05 | 1.09 |
Quick Ratio | 3.61 | 3.65 | 1.80 | 3.92 | 8.16 | 5.81 |
Current Ratio | 4.84 | 5.04 | 3.02 | 5.41 | 12.69 | 8.05 |
Return on Equity (ROE) | 17.63% | 17.72% | -0.63% | 16.97% | 24.77% | 22.22% |
Return on Assets (ROA) | 5.13% | 4.76% | 0.95% | 10.94% | 8.31% | 12.63% |
Return on Invested Capital (ROIC) | 8.39% | 7.50% | 1.81% | 18.24% | 13.84% | 20.95% |
Return on Capital Employed (ROCE) | 8.50% | 7.90% | 1.70% | 17.50% | 13.40% | 19.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.38% | 7.68% | -0.27% | 5.44% | 8.69% | 5.90% |
FCF Yield | 1.92% | 1.08% | -0.68% | 2.39% | 2.03% | 2.61% |
Dividend Yield | 3.50% | 3.81% | 3.33% | 2.54% | 6.13% | 3.26% |
Payout Ratio | 40.75% | 41.45% | - | 42.49% | 69.27% | 32.49% |
Buyback Yield / Dilution | 1.21% | 6.27% | -5.98% | 1.15% | 2.04% | -1.12% |
Total Shareholder Return | 4.71% | 10.08% | -2.66% | 3.69% | 8.17% | 2.15% |